Vimian Group (VIMIAN) Resumen de Acciones
Vimian Group AB (publ) se dedica al negocio de la salud animal en todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en VIMIAN a partir de nuestros controles de riesgos.
VIMIAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Vimian Group AB (publ)
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | SEK 29.30 |
| Máximo en las últimas 52 semanas | SEK 46.00 |
| Mínimo de 52 semanas | SEK 24.18 |
| Beta | 1.19 |
| Cambio en 1 mes | -1.84% |
| Variación en 3 meses | 9.90% |
| Cambio de 1 año | -24.76% |
| Variación en 3 años | 3.31% |
| Variación en 5 años | n/a |
| Variación desde la OPV | -63.78% |
Noticias y actualizaciones recientes
Actualización de narrativa • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.
Actualización de narrativa • Apr 17
VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential
Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.Actualización de narrativa • Apr 03
VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential
Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.Recent updates
Actualización de narrativa • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.Actualización de narrativa • Apr 17
VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential
Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.Actualización de narrativa • Apr 03
VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential
Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.Actualización de narrativa • Mar 20
VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance
Analysts have trimmed their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on growth, margins and valuation multiples that align the target more closely with recent research views. Analyst Commentary Recent research reflects a cautious tone around Vimian Group, with the latest move being a trim in the price target to SEK 25 from SEK 27.Actualización de narrativa • Mar 05
VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects
Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
Actualización de narrativa • Feb 19
VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment
Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.Artículo de análisis • Feb 16
Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Vimian Group AB (publ) ( STO:VIMIAN ) had a good week, as its shares rose 5.9% to close at kr27.84...Artículo de análisis • Feb 05
Is Vimian Group (STO:VIMIAN) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Actualización de narrativa • Feb 05
VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade
Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.Actualización de narrativa • Jan 22
VIMIAN: Rebased Expectations Will Spotlight Execution Under New Leadership Transition Narrative
Analysts have reduced their fair value estimate for Vimian Group to SEK 41.36 from SEK 41.97, citing slightly higher discount rate assumptions and updated sector views. This follows a recent cut in the Street price target to SEK 27 from SEK 37.Actualización de narrativa • Jan 08
VIMIAN: Rebased Expectations Will Highlight Execution On M&A-Led Expansion Narrative
Analysts have lowered their fair value estimate for Vimian Group from SEK 51.65 to SEK 41.97, citing more cautious assumptions on revenue growth and valuation multiples in line with recent price target cuts, including the move to SEK 27 from SEK 37 in Barclays' 2026 industry outlook. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with fair value and price targets recalibrated to reflect updated assumptions on revenue growth and sector valuation.Artículo de análisis • Jan 08
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Actualización de narrativa • Dec 23
VIMIAN: Downgrade And New CEO Will Shape Medium Term Risk Outlook
Analysts have lowered their price target on Vimian Group from approximately SEK 37 to around SEK 27. This reflects more cautious assumptions on growth, profitability, and valuation multiples in line with a more conservative sector outlook for 2026.Actualización de narrativa • Dec 09
VIMIAN: Future Leadership Will Drive Cash Flow Execution Upside Despite Sector Downgrade
Analysts have trimmed their price target on Vimian Group by SEK 10 to SEK 27. This reflects slightly higher discount rate assumptions and more conservative long term valuation multiples for the sector.Actualización de narrativa • Nov 25
VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience
Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.Artículo de análisis • Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price
Key Insights The projected fair value for Vimian Group is kr43.69 based on 2 Stage Free Cash Flow to Equity Vimian...Actualización de narrativa • Sep 05
Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare
Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90. Analyst Commentary Ongoing execution challenges in the MedTech segment are impacting overall group momentum.Artículo de análisis • Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
OM:VIMIAN 1 Year Share Price vs Fair Value Explore Vimian Group's Fair Values from the Community and select yours...Artículo de análisis • Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights Vimian Group's estimated fair value is kr55.41 based on 2 Stage Free Cash Flow to Equity Vimian Group's...Artículo de análisis • May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely
With a median price-to-sales (or "P/S") ratio of close to 4.6x in the Medical Equipment industry in Sweden, you could...Artículo de análisis • Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem
Unsurprisingly, Vimian Group AB (publ)'s ( STO:VIMIAN ) stock price was strong on the back of its healthy earnings...Artículo de análisis • Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights The projected fair value for Vimian Group is kr54.92 based on 2 Stage Free Cash Flow to Equity Current...
Nueva narrativa • Feb 09
iM3 Acquisition Will Expand Presence In Veterinary Dental Space
Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.Artículo de análisis • Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Artículo de análisis • Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%
Vimian Group AB (publ) ( STO:VIMIAN ) shareholders have had their patience rewarded with a 27% share price jump in the...Artículo de análisis • Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Artículo de análisis • Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Vimian Group AB (publ)'s ( STO:VIMIAN ) robust earnings report didn't manage to move the market for its stock. Our...Artículo de análisis • Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vimian Group fair value estimate is kr55.14 Vimian Group's...Artículo de análisis • Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Artículo de análisis • Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Vimian Group AB (publ)'s ( STO:VIMIAN ) price-to-sales (or "P/S") ratio of 3.6x might make it look like a buy right now...Artículo de análisis • Dec 03
Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching
While Vimian Group AB (publ) ( STO:VIMIAN ) might not be the most widely known stock at the moment, it saw a...Artículo de análisis • Nov 01
There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Rentabilidad de los accionistas
| VIMIAN | SE Medical Equipment | Mercado SE | |
|---|---|---|---|
| 7D | -2.7% | 6.4% | 3.2% |
| 1Y | -24.8% | -1.8% | 14.4% |
Rentabilidad vs. Industria: Los resultados de VIMIAN fueron inferiores a los de la industria Swedish Medical Equipment, que obtuvo un rendimiento del -1.8% el año pasado.
Rentabilidad vs. Mercado: VIMIAN obtuvo unos resultados inferiores a los del mercado Swedish, que fueron del 14.4% el año pasado.
Volatilidad de los precios
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.7% |
Precio estable de las acciones: VIMIAN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Swedish.
Volatilidad a lo largo del tiempo: La volatilidad semanal de VIMIAN (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2020 | 1,300 | Alireza Tajbakhsh | vimian.com |
Vimian Group AB (publ) se dedica al negocio de la salud animal en todo el mundo. Opera a través de los segmentos Specialty Pharma, MedTech, Diagnostics y Veterinary Services. La empresa ofrece diagnósticos patentados y tratamientos con y sin receta para el cuidado preventivo y el tratamiento de enfermedades crónicas de animales de compañía bajo la marca Nextmune; y soluciones moleculares y de inmunodiagnóstico que utilizan los laboratorios para aplicaciones veterinarias específicas centradas en los mercados de la ganadería y la salud de los animales de compañía bajo la marca Indical Bioscience.
Resumen de fundamentos de Vimian Group AB (publ)
| Estadísticas fundamentales de VIMIAN | |
|---|---|
| Capitalización bursátil | SEK 15.51b |
| Beneficios(TTM) | SEK 399.69m |
| Ingresos (TTM) | SEK 4.71b |
38.8x
Ratio precio-beneficio (PE)3.3x
Ratio precio-ventas (PS)¿Está VIMIAN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de VIMIAN | |
|---|---|
| Ingresos | €433.60m |
| Coste de los ingresos | €134.40m |
| Beneficio bruto | €299.20m |
| Otros gastos | €262.40m |
| Beneficios | €36.80m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 17, 2026
| Beneficios por acción (BPA) | 0.07 |
| Margen bruto | 69.00% |
| Margen de beneficio neto | 8.49% |
| Ratio deuda/patrimonio | 31.5% |
¿Cómo se ha desempeñado VIMIAN a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 23:26 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Vimian Group AB (publ) está cubierta por 10 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | ABG Sundal Collier |
| Jonathon Unwin | Barclays |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |